The anti-proliferative activity of sabizabulin was determined in two conventional HER2+ breast cancer cell lines, BT474 (ER+/PR+/HER2+) and SKBR3 (ER-/PR-/HER2+). The gene discussed is ESR1; the disease is breast carcinoma.